ADLM 2025: Key Takeaways in Diagnostics

Automation offerings were increasingly modular and designed to integrate into existing laboratory layouts without requiring a full rebuild. Pre-analytical automation, including automated decapping, aliquoting, and integrated cleaning, was a recurring focus. The emphasis was on preventing workflow interruptions through better exception handling and sample routing rather than chasing maximum theoretical throughput.

Why it matters: Staffing shortages remain a significant constraint for many laboratories. By targeting the most frequent bottlenecks, these systems deliver measurable daily efficiency without the capital expense or downtime of a full-line replacement.

Manufacturers favored targeted menu additions that reduce send-outs and keep analyzers running at higher utilization. Chemistry and immunoassay platforms added specialized tests with steady daily demand. Microbiology systems focused on faster organism identification and antimicrobial susceptibility testing. Molecular systems introduced smaller, everyday assays rather than relying on large panels or crisis-driven volumes.

Why it matters: Expanding within existing systems allows labs to improve service levels and reduce turnaround times without adding new instrument lines, while also stabilizing reagent usage and cost per reportable result.

Liquid chromatography–mass spectrometry continued to move from a specialist tool into the broader core laboratory environment. New platforms emphasized simplified sample preparation, validated reagent kits, and workflow guardrails to reduce the need for highly specialized operators. Early adoption in therapeutic drug monitoring, steroid hormone testing, and vitamin D measurement demonstrates where LC-MS is already delivering operational and clinical benefits.

Why it matters: LC-MS offers specificity and supply chain resilience in areas where immunoassay has limitations. Making it easier to implement expands the range of labs that can bring these capabilities in-house.

Software improvements were central to many new platform launches. QC tools with anomaly detection, triage queues, and automated commenting help laboratories process results faster while maintaining compliance. Device analytics are now being applied to inventory planning and predictive maintenance, reducing downtime risk. Connectivity advances, including stronger HL7 and FHIR compatibility, reduce the complexity and cost of LIS integration.

Why it matters: Software is now a competitive differentiator in instrument procurement. In a constrained labor environment, features that reduce manual review or unplanned downtime can deliver more impact than raw throughput increases.

The largest global players, Roche, Abbott, Siemens, Thermo Fisher, Danaher, bioMérieux, Sysmex, and BD, remained dominant in presence and portfolio breadth. The recent acquisition of BD’s IVD business by Waters was a common discussion point, with speculation on how it might reshape menu strategy, technology integration, and competitive positioning. Smaller companies continued to focus on highly specialized technologies, often with the goal of proving value in a niche and then partnering with or being acquired by a larger manufacturer. Supply chain resilience and regulatory readiness were consistent purchasing criteria, with vendors highlighting dual sourcing, regional manufacturing, and complete compliance documentation.

Why it matters: Consolidation at the top can alter technology access, reagent supply security, and market pricing, while smaller innovators remain an important source of category-defining solutions.

ADLM 2025 reinforced that the most widely adopted innovations will be those that deliver clear operational gains without major infrastructure changes. Modular automation, focused menu expansion, accessible LC-MS, and integrated software tools are well positioned to drive measurable value over the next 12 months. Market consolidation will likely continue, with competitive advantage going to companies that can combine scale with flexibility. By ADLM 2026, expect to see more laboratories piloting targeted LC-MS applications, expanding test menus within existing analyzers, and using software analytics to make real-time operational decisions.